Two growth stocks I think could make you richer

These two stocks are thriving despite the weak markets and I think they are poised for enormous growth.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Falling markets are presenting investors with a lot of buying opportunities but looking for stocks that are still rising can be the best strategy for spotting hidden gems. AB Dynamics (LSE:ABDP) is an advanced vehicle testing company that could grow significantly from its specialisation in self-driving cars. I mentioned it as a good momentum buy back in October and it has gained 11% since then, despite flailing market sentiment in the UK generally.

Big upgrades

Whenever a company boasts in its trading statement for the first six months of the year that results will be “significantly ahead of market expectations” as it did back in October, I think it’s worth taking a closer look. When H1 results were released it revealed revenue increased 51% and earnings-per-share increased 70%, so it didn’t disappoint.

Looking ahead, it is releasing several new products and told us it has strong orders through next year. It is expanding internationally and has indicated that there is growing demand for its vehicle-testing services. Factoring all of this in, I think it is a very exciting time to be holding this share.

But I’m taking a wait and see approach for now. My main reservation currently is that directors have been very busy selling shares recently. While management can’t be faulted for cashing in some profits, the sizes of the holdings are significant. It looks like eight directors in total have offloaded shares with some selling over 50% of their holdings. But Anthony Best (the AB in the company’s name) sold a small amount and still retains over 30% ownership of the company, which is encouraging.

Also it had a new CEO as of October which can signal a change in fortunes so I’d wait for confirmation that progress is continuing before buying.

Growing ahead of demand

Sopheon (LSE:SPE) is a computer software company that has also been thriving recently. It is up 15% since October on the back of a big upgrade in forecasts. It provides software that helps companies produce estimates, and subsequently savings, through lifecycle management.

The trouble with this company is that its revenue guidance makes it very difficult to value. We have to do a bit of puzzle-solving to get an approximate figure. Revenue for 2018 was forecast at $31m (despite being listed on AIM, it reports in dollars) but in its half-year results it was stated that “revenue visibility for the year [is] already at $27.2m”. However it has since stated that it had a record Q3 and that visibility is now above $30m with two new deals in chemicals and electronics. Since then it has released news of an additional contract with The Nature’s Bounty Co. This is a billion dollar health firm so presumably this could have pushed revenue over revised forecasts of $32.5m.

These constant upwards revisions leave a lot of room for speculation, so I would conjecture that revenue will be in the mid-30s. Its deals are large but infrequent, so it would be risky to assume that it will be higher. Regardless of the exact figure, this company is growing so quickly that the share price can’t keep up. With this in mind, I’d consider buying into this company.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Robert Faulkner has no position in any of the shares mentioned. The Motley Fool UK has recommended AB Dynamics. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »